Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Depreciation and Depletion (2018 - 2024)

Alaunos Therapeutics (TCRT) has disclosed Depreciation and Depletion for 7 consecutive years, with -$1000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation and Depletion fell 100.41% year-over-year to -$1000.0, compared with a TTM value of $2000.0 through Dec 2024, down 99.91%, and an annual FY2024 reading of $2000.0, down 99.91% over the prior year.
  • Depreciation and Depletion was -$1000.0 for Q4 2024 at Alaunos Therapeutics, down from $1000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $708000.0 in Q4 2021 and bottomed at -$1000.0 in Q4 2024.
  • Average Depreciation and Depletion over 5 years is $463368.4, with a median of $673000.0 recorded in 2021.
  • The sharpest move saw Depreciation and Depletion skyrocketed 280.28% in 2021, then crashed 100.41% in 2024.
  • Year by year, Depreciation and Depletion stood at $420000.0 in 2020, then surged by 68.57% to $708000.0 in 2021, then decreased by 1.98% to $694000.0 in 2022, then plummeted by 65.27% to $241000.0 in 2023, then plummeted by 100.41% to -$1000.0 in 2024.
  • Business Quant data shows Depreciation and Depletion for TCRT at -$1000.0 in Q4 2024, $1000.0 in Q2 2024, and $2000.0 in Q1 2024.